Conclusion
For this rapidly evolving pandemic, the development of a specific antiviral agent against the virus is of course what is needed, but series of preclinical trials before any novel agent becomes available for clinical use makes it an improbable option. Thus, the need of the hour would be to assess the available armoury of drugs and use them in defence against the current enemy.